Pacobra

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Schisandra chinensis, Quantity: 50 mg (Equivalent: Schisandra chinensis, Qty 250 mg); Paullinia cupana, Quantity: 18.75 mg (Equivalent: Paullinia cupana, Qty 75 mg; Equivalent: caffeine, Qty 2.06 mg); Panax ginseng, Quantity: 50 mg (Equivalent: Panax ginseng, Qty 250 mg); Ginkgo biloba, Quantity: 60 mg (Equivalent: Ginkgolides, Qty 1.86 mg; Equivalent: Ginkgolides and bilobalide, Qty 3.6 mg; Equivalent: Ginkgo flavonglycosides, Qty 14.7 mg; Equivalent: Ginkgo biloba, Qty 3000 mg); Bacopa monnieri, Quantity: 75 mg (Equivalent: Bacopa monnieri, Qty 1500 mg; Equivalent: bacosides calculated as bacoside A (of Bacopa monnieri), Qty 33.75 mg)

Available from:

Pharmametics Products A Division of Max Biocare Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: crospovidone; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; povidone; colloidal anhydrous silica; magnesium stearate; Carnauba Wax; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; lecithin; medium chain triglycerides

Administration route:

Oral

Therapeutic indications:

Antioxidant/Reduce free radicals formed in the body ; Helps enhance/promote general health and wellbeing ; Helps enhance/promote healthy blood circulation ; Maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet) ; Enhance/promote body adaptation to stress ; Support healthy stress response in the body ; Maintain/support mental concentration/focus/clarity ; Maintain/support cognitive function/mental function ; Maintain/support learning and information processing ; Maintain/support memory/mental recall ; Maintain/support brain function ; Maintain/support nervous system function

Product summary:

Visual Identification: ; Container Type: Multiple containers

Authorization status:

Listed

Authorization date:

2019-03-07